WO2021009509A1 - Monotosylate d'umbralisib amorphe - Google Patents

Monotosylate d'umbralisib amorphe Download PDF

Info

Publication number
WO2021009509A1
WO2021009509A1 PCT/GB2020/051701 GB2020051701W WO2021009509A1 WO 2021009509 A1 WO2021009509 A1 WO 2021009509A1 GB 2020051701 W GB2020051701 W GB 2020051701W WO 2021009509 A1 WO2021009509 A1 WO 2021009509A1
Authority
WO
WIPO (PCT)
Prior art keywords
umbralisib
monotosylate
amorphous
solvent
crystalline
Prior art date
Application number
PCT/GB2020/051701
Other languages
English (en)
Inventor
Na Yao
Original Assignee
Johnson Matthey Public Limited Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson Matthey Public Limited Company filed Critical Johnson Matthey Public Limited Company
Priority to CN202080051449.4A priority Critical patent/CN114127074A/zh
Priority to EP20747081.6A priority patent/EP3999511A1/fr
Priority to BR112022000684A priority patent/BR112022000684A2/pt
Priority to CA3146785A priority patent/CA3146785A1/fr
Priority to KR1020227004535A priority patent/KR20220035169A/ko
Priority to US17/597,634 priority patent/US20220251091A1/en
Priority to JP2022501041A priority patent/JP2022540466A/ja
Publication of WO2021009509A1 publication Critical patent/WO2021009509A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present disclosure relates to an amorphous form of umbralisib monotosylate and to methods of preparing the same.
  • the present disclosure also relates to
  • compositions comprising the form and methods for treating disease using the form.
  • Umbralisib having the chemical designation (S)-2-(l-(4-amino-3-(3-fluoro-4- isopropoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)-6-fluoro-3-(3- fluorophenyl)-4H-chromen-4-one, is an orally available PI3K delta inhibitor.
  • Umbralisib has the following structure:
  • umbralisib Inhibition of PI3K delta signaling with umbralisib has demonstrated activity in several pre-clinical models and primary cells from patients with hematologic malignancies.
  • umbralisib provided effective PI3K-delta inhibition and appeared well-tolerated among patients with relapsed/refractory marginal zone lymphoma.
  • Umbralisib is currently in Phase 3 clinical development in combination with ublituximab for patients with hematologic malignancies.
  • Hematologic malignancies are forms of cancer that begin in the cells of blood-forming tissue, such as the bone marrow, or in the cells of the immune system.
  • hematologic cancer examples include acute and chronic leukemias, lymphomas, multiple myeloma and myelodysplastic syndromes.
  • Lymphomas can include follicular lymphoma (FL), small lymphocytic lymphoma (SLL), non-Hodgkin lymphoma (NHL), and diffuse large B-cell lymphoma (DLBCL), among others.
  • Leukemia can include chronic lymphocytic leukemia (CLL), among others.
  • the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to umbralisib for the treatment of patients with follicular lymphoma and for the treatment of patients with nodal, extranodal, and splenic marginal zone lymphoma.
  • U.S. Patent No. 9,150,579 discloses umbralisib and pharmaceutically acceptable salts thereof, such as 4-methylbenzenesulfonate (also known as tosylate), sulphate, hydrochloride, benzenesulfonate, maleate, and camphor sulfonate salts.
  • U.S. Patent Nos. 9,969,740 and 10,414,773 and U.S. Patent Application Publication No. 2019/0382411 disclose solid state forms of a p-toluenesulfonic acid salt (PTSA) of umbralisib. None of these references disclose an amorphous form of umbralisib monotosylate.
  • PTSA p-toluenesulfonic acid salt
  • An amorphous form of a compound is considered to be a solid state form that lacks long-range order relative to crystalline solid state forms of the compound.
  • the amorphous form is chemically identical to other crystalline solid state forms but can exhibit different physical properties such as intrinsic solubility, rate of dissolution, density, mechanical property, chemical and physical stability, hygroscopicity, and morphology.
  • the differences in intrinsic solubility also may lead to a difference in the rate of absorption, thus impacting bioavailability.
  • amorphous compounds have a higher solubility than crystalline compounds.
  • the present invention is directed to an amorphous form of umbralisib
  • the present invention is further directed to processes for the preparation of an amorphous form of umbralisib monotosylate.
  • the present invention also is directed to pharmaceutical compositions comprising amorphous umbralisib monotosylate, and a method for treating disease using amorphous umbralisib monotosylate.
  • FIG. 1 provides a representative XRPD pattern of amorphous umbralisib monotosylate prepared by dry grinding, expressed in terms of °2Q.
  • FIG. 2 provides a representative mDSC plot of amorphous umbralisib
  • FIG. 3 provides a representative DVS plot of amorphous umbralisib monotosylate prepared by dry grinding.
  • FIG. 4 provides representative sorption isotherm results of amorphous umbralisib monotosylate prepared by dry grinding.
  • FIG. 5 provides a representative XRPD pattern of amorphous umbralisib monotosylate prepared by dry grinding, after DVS, expressed in terms of °2Q.
  • FIG. 6 provides a representative XRPD pattern of amorphous umbralisib monotosylate prepared by evaporation in methanol, expressed in terms of °2Q.
  • FIG. 7 provides a representative mDSC plot of amorphous umbralisib
  • FIG. 8 provides a representative TGA plot of amorphous umbralisib monotosylate prepared by evaporation in methanol.
  • FIG. 9 provides a representative DVS plot of amorphous umbralisib monotosylate prepared by evaporation in methanol.
  • FIG. 10 provides representative sorption isotherm results of amorphous umbralisib monotosylate prepared by evaporation in methanol.
  • FIG. 11 provides a representative XRPD pattern of amorphous umbralisib monotosylate prepared by evaporation in methanol, after DVS, expressed in terms of °2Q.
  • FIG. 12 provides a representative 'H-NMR plot of amorphous umbralisib monotosylate prepared by evaporation in methanol.
  • FIG. 13(a) provides a representative FTIR spectra for amorphous umbralisib monotosylate prepared by evaporation in methanol and FIG 13(b) provides a
  • FIG. 14 provides a representative XRPD pattern of amorphous umbralisib monotosylate prepared by evaporation in methanol, after storage at 40 °C under vacuum conditions for 2 weeks.
  • FIG. 15 provides a representative mDSC of amorphous umbralisib monotosylate prepared by evaporation in methanol, after storage at 40 °C under vacuum conditions for 2 weeks.
  • FIG. 16 provides a representative XRPD pattern of amorphous umbralisib monotosylate prepared according to Example 3, expressed in terms of °20.
  • a specific temperature or temperature range such as, e.g., that describing a DSC or TGA thermal event, including, e.g., melting, dehydration
  • the term“pharmaceutical composition” is intended to encompass a pharmaceutically effective amount of the amorphous umbralisib monotosylate and at least one pharmaceutically acceptable excipient.
  • the term“pharmaceutical compositions” includes
  • compositions such as tablets, pills, powders, liquids, suspensions, emulsions, granules, capsules, suppositories, or injection preparations.
  • excipient refers to a pharmaceutically acceptable organic or inorganic carrier substance.
  • Excipients may be natural or synthetic substances formulated alongside the active ingredient of a medication, included for the purpose of bulking-up formulations that contain potent active ingredients (thus often referred to as“bulking agents,”“fillers,” or“diluents”), or to confer a therapeutic enhancement on the active ingredient in the final dosage form, such as facilitating drug absorption or solubility.
  • Excipients can also be useful in the manufacturing process, to aid in the handling of the active substance, such as by facilitating powder flowability or non-stick properties, in addition to aiding in vitro stability such as prevention of denaturation over the expected shelf life.
  • the term“patient” refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
  • the patient has experienced and/or exhibited at least one symptom of the disease or disorder to be treated and/or prevented.
  • a patient may not have exhibited any symptoms of the disorder, disease or condition to be treated and/or prevented, but has been deemed by a physician, clinician or other medical professional to be at risk for developing said disorder, disease or condition.
  • polymorph As used herein and unless otherwise specified, the terms“polymorph,” “polymorphic form” or related term herein, refer to a crystal form of a molecule, or salt thereof that can exist in two or more forms, as a result of different arrangements or conformations of the molecule or salt thereof of ions in the crystal lattice of the polymorph.
  • the terms“treat,”“treating” and “treatment” refer to the eradication or amelioration of a disease or disorder, or of one or more symptoms associated with the disease or disorder. In certain embodiments, the terms refer to minimizing the spread or worsening of the disease or disorder resulting from the administration of one or more therapeutic agents to a patient with such a disease or disorder. In some embodiments, the terms refer to the administration of a compound provided herein, with or without other additional active agents, after the onset of symptoms of the particular disease.
  • DSC differential scanning calorimetry
  • TGA thermal gravimetric analysis
  • DVS dynamic vapor sorption
  • XRPD X-ray powder diffractometry
  • 'H-NMR proton nuclear magnetic resonance
  • FTIR Fourier transform infrared spectroscopy
  • Modulated DSC (mDSC) data are collected using a TA Instruments Q2000 DSC. Approximately, samples (2-5 mg) are placed in sealed hermetic aluminum sample pans and mDSC is carried out with modulation ⁇ 0.5 °C every 60 s and measured from about 5 °C to about 300 °C at the heating rate of about 1.5 °C/min under a nitrogen purge of about 50 mL/min.
  • TGA data are collected using a TA Instruments TGA Q500. Approximately, samples (2-5 mg) are placed in an open, pre-tared aluminum sample pan and scanned from about 25 to about 350 °C at a rate of about 10 °C/min using a nitrogen purge at about 60 mL/min.
  • the °20 values and the relative intensity values are generated by performing a peak search on the measured data and the d-spacing values are calculated by the instrument from the °20 values using Bragg’s equation.
  • the relative intensity for the measured peaks may vary as a result of sample preparation, orientation and instrument used, for example.
  • H-NMR data are collected using a Bruker Ascend 600 MHz NMR equipped with TopSpin software. Samples are prepared by dissolving the compound in deuterated dimethylsulfoxide with 0.05% (v/v) tetramethylsilane (TMS). Spectra are collected at 298 K. The number of scans is 16 for 1 H-NMR.
  • FTIR spectra are collected using a Thermo Scientific Nicolet iS5. Samples are ground with a mortar and pestle into a mixture of 95% KBr, then pressed by hand into pellets using a Little-Press KBr Pellet Die Kit. The number of scans is 16 for each measurement.
  • DVS samples (5-10 mg) are analyzed using a TA Instruments Q5000 SA powerful dynamic vapor sorption analyzer.
  • the relative humidity is started at about 50% and adjusted to between about 0-90% humidity with about a 10% increase or decrease in humidity for each step for 3 cycles.
  • the weight of the sample is continuously monitored and recorded.
  • the present disclosure is directed to amorphous umbralisib monotosylate, processes for the preparation of amorphous umbralisib monotosylate, pharmaceutical compositions comprising amorphous umbralisib monotosylate, and its use for treating a patient with a physiological condition in need of treatment, as herein described in detail.
  • the process for preparing amorphous umbralisib is directed to amorphous umbralisib monotosylate, processes for the preparation of amorphous umbralisib monotosylate, pharmaceutical compositions comprising amorphous umbralisib monotosylate, and its use for treating a patient with a physiological condition in need of treatment, as herein described in detail.
  • monotosylate first comprises the preparation of umbralisib tosylate salt by reactive crystallization of umbralisib free base with p-toluenesulfonic acid (PTSA) in ethyl acetate.
  • PTSA p-toluenesulfonic acid
  • the umbralisib free base and p-toluenesulfonic acid are present in about a 1 : 1 ratio.
  • umbralisib free base and p- toluenesulfonic acid are each dissolved separately in ethyl acetate. The two solutions are then mixed together and stirred at room temperature for a period of time.
  • the mixed solution is stirred overnight (about 8-12 h) to effect precipitation of crystalline umbralisib tosylate salt. If precipitation does not occur, the mixed solution may be transferred to a lower temperature, for example to about 5 °C, to assist in the formation of a precipitate. For a larger scale, for example, greater than about 800 mg, seeds can be added to the mixed solution to induce the reaction.
  • a solid crystalline umbralisib tosylate salt is obtained by filtration.
  • the crystalline umbralisib tosylate salt obtained according to the above procedure is dried under vacuum at about 40 °C in an oven for a period of time, for example, for about 3 days, to remove any residual ethyl acetate.
  • amorphous umbralisib monotosylate can be prepared from crystalline umbralisib tosylate salt, for example using the crystalline salt prepared by above process, or alternatively from any crystalline umbralisib tosylate salt known in the art, for example, Form A or Form B disclosed in U.S. Patent No.
  • the process of the invention comprises a) grinding crystalline umbralisib tosylate salt, preferably dried, using a mortar and pestle to yield amorphous umbralisib monotosylate.
  • the grinding is conducted for about 3 minutes.
  • the process of the invention comprises a) dissolving crystalline umbralisib tosylate salt in a solvent, and b) evaporating the solvent to yield amorphous umbralisib monotosylate.
  • the dissolving is carried out at an elevated temperature, for example, about 50 °C.
  • the solvent is an alcoholic solvent; more particularly, the solvent is methanol.
  • the solvent is evaporated at an elevated temperature under vacuum; more particularly, the solvent is evaporated under vacuum at about 40 °C in an oven overnight (about 8-12 h).
  • the process of the invention comprises a) forming umbralisib monotosylate in solution (without isolation of
  • umbralisib free base and p-toluenesulfonic acid are dissolved in solution.
  • the solution is an C1-3 alcohol; more particularly, methanol.
  • the umbralisib free base and PTSA are present in a 1 : 1 ratio.
  • the umbralisib free base and p- toluenesulfonic acid are each separately dissolved in methanol and then the two methanolic solutions are mixed together.
  • the umbralisib free base and p-toluenesulfonic acid are dissolved in methanol at an elevated temperature, for example, at about 50 °C.
  • the mixed solution is stirred for about 1-3 h. In one embodiment, the mixed solution is first stirred for about 1-3 h at room temperature and then stirred at about 4 °C overnight for about 8-12 h. In a further embodiment, the evaporating is carried out at about 40 °C in a vacuum oven overnight for about 8-12 h.
  • An embodiment of the invention is directed to amorphous umbralisib
  • a further embodiment of the invention is amorphous umbralisib monotosylate prepared by a process embodiment as described herein.
  • Amorphous umbralisib monotosylate is a white solid identified as amorphous by XRPD.
  • the amorphous umbralisib monotosylate obtained by dry grinding has a glass transition temperature (T g ) of about 51 °C.
  • Amorphous umbralisib monotosylate obtained using crystalline umbralisib tosylate salt as the starting material and evaporating from methanol has a T g of about 75 °C.
  • the T g of amorphous umbralisib monotosylate can vary depending upon its preparation method.
  • amorphous umbralisib monotosylate is stored under dry conditions, for example, under vacuum, in the presence of a desiccant, or with low levels of humidity, for example, about 15% or less.
  • compositions comprising amorphous umbralisib monotosylate and a pharmaceutically acceptable excipient.
  • Pharmaceutical compositions containing amorphous umbralisib monotosylate may be prepared according to any method known in the art.
  • the present disclosure also provides for a method of treating disease by administering to a patient, in need thereof, pharmaceutical compositions comprising amorphous umbralisib monotosylate.
  • Diseases intended to be treated include
  • CLL chronic lymphocytic leukemia
  • DLBCL diffuse large B-cell lymphoma
  • NHL non-Hodgkin lymphoma
  • B-cell lymphoma B-cell lymphoma
  • T-cell lymphoma B-cell lymphoma
  • NHL non-Hodgkin lymphoma
  • I-NHL Indolent Non- Hodgkin's Lymphoma
  • MCL mantle cell lymphoma
  • follicular lymphoma and
  • the dosage of the pharmaceutical compositions may be varied over a wide range. Optimal dosages and dosage regimens to be administered may be readily determined by those skilled in the art, and will vary with the mode of administration, the strength of the preparation and the advancement of the disease condition. In addition, factors associated with the particular patient being treated, including patient’s sex, age, weight, diet, physical activity, time of administration and concomitant diseases, will result in the need to adjust dosages and/or regimens.
  • Example 1 provides embodiments of the preparation of amorphous umbralisib monotosylate.
  • Example 1 provides embodiments of the preparation of amorphous umbralisib monotosylate.
  • Form I of umbralisib tosylate salt is dried under vacuum at about 40 °C in an oven for at least about 3 days to remove any residual ethyl acetate. About 30 mg of the dried umbralisib tosylate salt is ground manually using a mortar (about 6 cm in diameter) and pestle for about 3 minutes. The ground umbralisib tosylate salt is identified as being amorphous by XRPD.
  • FIG. 1 is a representative XPRD pattern for amorphous umbralisib monotosylate prepared according to Example 1.
  • the amorphous umbralisib monotosylate prepared according to Example 1 is characterized by a T g of about 51 °C, as depicted in the mDSC thermogram contained in FIG. 2.
  • a DVS of amorphous umbralisib monotosylate prepared according to Example 1 indicates the sample is hygroscopic, with about a 4% weight change between about 0- 90% relative humidity, as depicted in FIG. 3, and less than about a 1% weight change in the sample over three cycles, as depicted in FIG. 4.
  • An XRPD pattern of the sample after DVS indicates that the sample is still amorphous, as depicted in FIG. 5.
  • FIG. 6 is a representative XPRD pattern for amorphous umbralisib monotosylate prepared according to Example 2.
  • the amorphous umbralisib monotosylate prepared according to Example 2 is characterized by a T g of about 75 °C, as depicted in the mDSC thermogram contained in FIG. 7.
  • a TGA of amorphous umbralisib monotosylate prepared according to Example 2 shows about a 0.9% weight loss up to about 120 °C, as depicted in FIG. 8.
  • a DVS of amorphous umbralisib monotosylate prepared according to Example 2 indicates that the sample is hygroscopic, with about a 4% weight change between about 0-90% relative humidity, as depicted in FIG. 9, with about a 0.5% weight change in the sample over three cycles, as depicted in FIG. 10.
  • An XRPD pattern of the sample after DVS indicates that the sample is still amorphous, as depicted in FIG. 11.
  • FTIR spectra is collected on amorphous umbralisib monotosylate prepared according to Example 2, as depicted in FIG. 13(a) and on starting crystalline umbralisib tosylate salt, as depicted in FIG. 13(b).
  • Example 3 XRPD of amorphous umbralisib monotosylate prepared according to Example 2 after storage at about 40 °C under vacuum conditions for about two weeks indicates that the sample is still amorphous, as depicted in FIG. 14. Further, mDSC of amorphous umbralisib monotosylate after storage at about 40 °C under vacuum conditions for about two weeks indicates that the T g is increased to about 83 °C, as depicted in FIG. 15.
  • Umbralisib free base and p-toluenesulfonic acid are each separately dissolved in MeOH. Specifically, about 72 mg of umbralisib free base is dissolved in about 3mL of MeOH at about 50 °C and about 24 mg of p-toluenesulfonic acid is dissolved in about 0.25 mL of MeOH at about 50 °C. The two solutions are mixed and stirred at room temperature for about 1 hr and then at about 4 °C overnight. The solution is transferred to a vacuum oven at about 40 °C overnight to evaporate the MeOH. Amorphous umbralisib monotosylate, identified by XRPD, is obtained. FIG. 16 is a representative XPRD pattern for amorphous umbralisib monotosylate prepared according to Example 3.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne du monotosylate d'umbralisib amorphe, et des procédés pour sa préparation; des compositions pharmaceutiques comprenant du monotosylate d'umbralisib amorphe; et une méthode de traitement d'un patient à l'aide de monotosylate d'umbralisib amorphe.
PCT/GB2020/051701 2019-07-15 2020-07-15 Monotosylate d'umbralisib amorphe WO2021009509A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN202080051449.4A CN114127074A (zh) 2019-07-15 2020-07-15 无定形乌帕拉尼单甲苯磺酸盐
EP20747081.6A EP3999511A1 (fr) 2019-07-15 2020-07-15 Monotosylate d'umbralisib amorphe
BR112022000684A BR112022000684A2 (pt) 2019-07-15 2020-07-15 Monotosilato de umbralisibe, processo para preparar uma forma amorfa, forma amorfa de monotosilato de umbralisibe, composição farmacêutica, e, método de tratamento de doença
CA3146785A CA3146785A1 (fr) 2019-07-15 2020-07-15 Monotosylate d'umbralisib amorphe
KR1020227004535A KR20220035169A (ko) 2019-07-15 2020-07-15 비정질 움브랄리십 모노토실레이트
US17/597,634 US20220251091A1 (en) 2019-07-15 2020-07-15 Amorphous umbralisib monotosylate
JP2022501041A JP2022540466A (ja) 2019-07-15 2020-07-15 非晶質ウムブラリシブモノトシレート

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962874207P 2019-07-15 2019-07-15
US62/874,207 2019-07-15

Publications (1)

Publication Number Publication Date
WO2021009509A1 true WO2021009509A1 (fr) 2021-01-21

Family

ID=71842698

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2020/051701 WO2021009509A1 (fr) 2019-07-15 2020-07-15 Monotosylate d'umbralisib amorphe

Country Status (8)

Country Link
US (1) US20220251091A1 (fr)
EP (1) EP3999511A1 (fr)
JP (1) JP2022540466A (fr)
KR (1) KR20220035169A (fr)
CN (1) CN114127074A (fr)
BR (1) BR112022000684A2 (fr)
CA (1) CA3146785A1 (fr)
WO (1) WO2021009509A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230140482A (ko) 2022-03-22 2023-10-06 주식회사 엘지에너지솔루션 전지 셀에서의 리튬 석출 검사 장치 및 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150579B2 (en) 2012-07-04 2015-10-06 Rhizen Pharmaceuticals Sa Selective PI3K delta inhibitors
US9969740B2 (en) 2014-05-27 2018-05-15 Rhizen Pharmaceuticals Sa Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1938005A (zh) * 2004-06-01 2007-03-28 特瓦药厂私人有限公司 制备药物的无定形形式的方法
TW201629054A (zh) * 2015-02-07 2016-08-16 廣東東陽光藥業有限公司 二氫嘧啶衍生物的複合物及其在藥物中的應用
US10966977B2 (en) * 2016-05-27 2021-04-06 Tg Therapeutics, Inc. Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders
AU2017322501A1 (en) * 2016-09-09 2019-03-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combination of an anti-CD20 antibody, PI3 kinase-delta inhibitor, and anti-PD-1 or anti-PD-L1 antibody for treating hematological cancers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150579B2 (en) 2012-07-04 2015-10-06 Rhizen Pharmaceuticals Sa Selective PI3K delta inhibitors
US9969740B2 (en) 2014-05-27 2018-05-15 Rhizen Pharmaceuticals Sa Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations
US10414773B2 (en) 2014-05-27 2019-09-17 Rhizen Pharmaceuticals Sa Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations
US20190382411A1 (en) 2014-05-27 2019-12-19 Rhizen Pharmaceuticals Sa Forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Remington: The Science and Practice of Pharmacy", 2005, LIPPINCOTT, WILLIAMS AND WILKINS
"The United States Pharmacopeia", 1995, pages: 1843 - 1844

Also Published As

Publication number Publication date
US20220251091A1 (en) 2022-08-11
CA3146785A1 (fr) 2021-01-21
BR112022000684A2 (pt) 2022-03-03
KR20220035169A (ko) 2022-03-21
JP2022540466A (ja) 2022-09-15
EP3999511A1 (fr) 2022-05-25
CN114127074A (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
CN106715454B (zh) 烟酰胺核苷的结晶形式
CN105131003B (zh) 6,7‑不饱和‑7‑氨基甲酰基吗啡喃衍生物的晶体及其制备方法
US20220251091A1 (en) Amorphous umbralisib monotosylate
US20230374030A1 (en) Solid-state forms of relugolix
US10730836B2 (en) Forms of apremilast
US20210094961A1 (en) Form of ponatinib
TW202333676A (zh) 吡唑並〔３，４－ｄ〕嘧啶化合物之固體形式
EP2275425A1 (fr) Nouvelles formes cristallines de temozolomide
WO2020072860A1 (fr) Forme solide de niraparib
US20210395232A1 (en) Co-crystal forms of selinexor
US11306062B2 (en) Forms of fedratinib dihydrochloride
US11136314B2 (en) Forms of afatinib dimaleate
US20210246159A1 (en) Novel form of bardoxolone methyl
WO2019195827A1 (fr) Nouvelle forme d'ibrutinib
WO2019070698A1 (fr) Nouvelles formes d'ibrutinib
JP2023524622A (ja) ６－クロロ－７－（４－（４－クロロベンジル）ピペラジン－１－イル）－２－（１，３－ジメチル－１Ｈ－ピラゾール－４－イル）－３Ｈ－イミダゾ［４，５－ｂ］ピリジンの塩及び多形体
WO2021217180A1 (fr) Nouvelles formes de dichlorhydrate de pracinostat
WO2020072870A1 (fr) Formes co-cristallines du baricitinib
WO2022238389A2 (fr) Nouvelles formes d'entinostat
WO2019209908A1 (fr) Formes cristallines de dasatinib
CN115572292A (zh) 小檗碱丁二酸盐晶型及其制备方法和其组合物与应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20747081

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022501041

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3146785

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022000684

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20227004535

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020747081

Country of ref document: EP

Effective date: 20220215

ENP Entry into the national phase

Ref document number: 112022000684

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220113